Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Yidu Tech's 5-Year RORE % for the quarter that ended in Sep. 2023 was 0.00%.
The industry rank for Yidu Tech's 5-Year RORE % or its related term are showing as below:
HKSE:02158's 5-Year RORE % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 5.86 * Ranked among companies with meaningful 5-Year RORE % only.
Yidu Tech 5-Year RORE % Historical Data
The historical data trend for Yidu Tech's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Yidu Tech's 5-Year RORE %
For the Health Information Services subindustry, Yidu Tech's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yidu Tech's 5-Year RORE % Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Yidu Tech's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Yidu Tech's 5-Year RORE % falls into.
Yidu Tech 5-Year RORE % Calculation
Yidu Tech's 5-Year RORE % for the quarter that ended in Sep. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2023 and 5-year before.
Yidu Tech (HKSE:02158) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Yidu Tech 5-Year RORE % Related Terms
Thank you for viewing the detailed overview of Yidu Tech's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Yidu Tech offers healthcare Big Data. It is an AI cloud-based firm providing solutions and tools to aid in more informed decisions to drive better efficiency in clients' strategies. Its clients are hospitals, pharmaceutical, biotech and medical device firms, research institutions, insurance companies, patients, and regulators. It three business segments are: Big Data platform and solutions, which partners with hospitals and policymakers to drive better efficiency; life sciences solutions, which enables better probability of clinical trial success with less drug development time and cost; and health management solutions, which helps with patient management. The Big Data platform accounted for 33% of revenue, life science solutions 30%, and health management solutions 27%, in fiscal 2022.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02158 has been successfully added to your 